

Henry Ford Health

## Henry Ford Health Scholarly Commons

---

Public Health Sciences Articles

Public Health Sciences

---

5-1-2016

### Assessing differences in inhaled corticosteroid response by self-reported race-ethnicity and genetic ancestry among asthmatic subjects

Karen E. Wells  
*Henry Ford Health*

Sonia Cajigal

Edward L. Peterson  
*Henry Ford Health*, epeters1@hfhs.org

Brian K. Ahmedani  
*Henry Ford Health*, bahmeda1@hfhs.org

Rajesh Kumar

*See next page for additional authors*

Follow this and additional works at: [https://scholarlycommons.henryford.com/publichealthsciences\\_articles](https://scholarlycommons.henryford.com/publichealthsciences_articles)

---

#### Recommended Citation

Wells KE, Cajigal S, Peterson EL, Ahmedani BK, Kumar R, Lanfear DE, Burchard EG, Williams KL. Assessing differences in inhaled corticosteroid response by self-reported race-ethnicity and genetic ancestry among asthmatic subjects. *Journal of Allergy and Clinical Immunology* 2016; 137(5):1364-1369.

This Article is brought to you for free and open access by the Public Health Sciences at Henry Ford Health Scholarly Commons. It has been accepted for inclusion in Public Health Sciences Articles by an authorized administrator of Henry Ford Health Scholarly Commons.

---

**Authors**

Karen E. Wells, Sonia Cajigal, Edward L. Peterson, Brian K. Ahmedani, Rajesh Kumar, David E. Lanfear, Esteban G. Burchard, and Keoki L. Williams

# Assessing differences in inhaled corticosteroid response by self-reported race-ethnicity and genetic ancestry among asthmatic subjects



Karen E. Wells, MPH,<sup>a</sup> Sonia Cajigal, MD,<sup>b</sup> Edward L. Peterson, PhD,<sup>a</sup> Brian K. Ahmedani, PhD,<sup>c</sup> Rajesh Kumar, MD,<sup>d</sup> David E. Lanfear, MD, MS,<sup>b</sup> Esteban G. Burchard, MD, MPH,<sup>e,f</sup> and L. Keoki Williams, MD, MPH<sup>b,c</sup> *Detroit, Mich, Chicago, Ill, and San Francisco, Calif*

**Background:** Inhaled corticosteroids (ICSs) are the preferred treatment for achieving asthma control. However, little is known regarding the factors contributing to treatment response and whether treatment response differs by population group.

**Objective:** We sought to assess behavioral, sociodemographic, and genetic factors related to ICS response among African American and European American subjects with asthma.

**Methods:** Study participants were part of the Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-ethnicity (SAPPHIRE). The analytic sample included asthmatic subjects aged 12 to 56 years with greater than 12% bronchodilator reversibility and percent predicted FEV<sub>1</sub> of between 40% and 90%. Participants received 6 weeks of inhaled beclomethasone dipropionate. The primary measure of ICS response was a change in Asthma Control Test (ACT) score; the secondary measure was a change in prebronchodilator FEV<sub>1</sub>. Adherence was measured with electronic monitors. Genetic

ancestry was estimated for African American participants by using genome-wide genotype data.

**Results:** There were 339 study participants; 242 self-identified as African American and 97 as European American. Baseline ACT score, percent predicted FEV<sub>1</sub>, degree of bronchodilator response, and ICS adherence were significantly associated with ICS response. A baseline ACT score of 19 or less was useful in identifying those who would respond, as evidenced by the significant dose-response relationship with ICS adherence. Neither self-reported race-ethnicity among all participants nor proportion of African ancestry among African American participants was associated with ICS responsiveness.

**Conclusions:** Our findings suggest that baseline lung function measures and self-reported asthma control predict ICS response, whereas self-reported race-ethnicity and genetic ancestry do not. (J Allergy Clin Immunol 2016;137:1364-9.)

**Key words:** *Inhaled corticosteroids, Adherence, medication, asthma, African Continental Ancestry Group, respiratory function tests*

Discuss this article on the JACI Journal Club blog: [www.jaci-online.blogspot.com](http://www.jaci-online.blogspot.com).

From the Departments of <sup>a</sup>Public Health Sciences and <sup>b</sup>Internal Medicine and <sup>c</sup>the Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit; <sup>d</sup>the Department of Pediatrics, The Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago; and the Departments of <sup>e</sup>Bioengineering & Therapeutic Sciences and <sup>f</sup>Medicine, University of California San Francisco.

Supported by grants from the American Asthma Foundation (to E.G.B. and L.K.W.), the Flight Attendant Medical Research Institute (to E.G.B.), the Fund for Henry Ford Hospital (to D.E.L., B.K.A., and L.K.W.), the Robert Wood Johnson Foundation Amos Medical Faculty Development Program (to E.G.B.), the Sandler Foundation (to E.G.B.), and the following institutes of the National Institutes of Health: the National Institute of Allergy and Infectious Diseases (AI077439 to E.G.B. and AI079139 and AI061774 to L.K.W.); the National Heart, Lung, and Blood Institute (K23HL093023 to R.K., HL078885 and HL088133 to E.G.B. and HL118267 and HL079055 to L.K.W.); the National Institute of Environmental Health Sciences (ES015794 to E.G.B.); and the National Institute of Diabetes and Digestive and Kidney Diseases (DK064695 to L.K.W.).

Disclosure of potential conflict of interest: E. L. Peterson has received grants from the National Institutes of Health (NIH). B. K. Ahmedani has received grants from the NIH and the Fund for Henry Ford Hospital. L. K. Williams has received grants from the National Heart, Lung, and Blood Institute; the National Institute of Allergy and Infectious Diseases; the National Institute of Diabetes and Digestive and Kidney Diseases; and the American Asthma Foundation. The rest of the authors declare that they have no relevant conflicts of interest.

Received for publication October 28, 2015; revised December 15, 2015; accepted for publication December 19, 2015.

Available online March 22, 2016.

Corresponding author: Karen E. Wells, MPH, Department of Public Health Sciences, Henry Ford Health System, 1 Ford Place, 5C, Detroit, MI 48202. E-mail: [kewells1@aol.com](mailto:kewells1@aol.com).

The CrossMark symbol notifies online readers when updates have been made to the article such as errata or minor corrections

0091-6749/\$36.00

© 2016 American Academy of Allergy, Asthma & Immunology

<http://dx.doi.org/10.1016/j.jaci.2015.12.1334>

#### Abbreviations used

ACT: Asthma Control Test

BMI: Body mass index

ICS: Inhaled corticosteroid

SAPPHIRE: Study for Asthma Phenotypes and Pharmacogenomic Interactions by Race-ethnicity

by Race-ethnicity (SAPPHIRE), had similar enrollment criteria, and received the same 6-week ICS treatment course.

## METHODS

### Study population

The study population was comprised of participants in the Study of Asthma Phenotypes and Pharmacogenomic Interactions by Race-ethnicity (SAPPHIRE), which was approved by the Institutional Review Board at Henry Ford Health System. Potentially eligible subjects were first identified through the medical record based on age (12–56 years), prior diagnosis of asthma, and lack of excluding diagnoses (ie, chronic obstructive pulmonary disease, congestive heart failure, or both). Subjects who met these criteria and who lived in southeast Michigan were invited for a clinical evaluation. Study participants (or their guardians in the case of minors) provided written consent before evaluation and study enrollment. Evaluation consisted of a staff-administered survey, vital sign and anthropomorphic measurements, and lung function tests. Race-ethnicity was based on subjects self-report at the initial study visit.

Lung function testing was performed with a Fleisch-type pneumotachometer in accordance with 2005 American Thoracic Society/European Respiratory Society guidelines for spirometry.<sup>10</sup> Bronchodilator response was defined as a greater than 12% improvement in FEV<sub>1</sub> after albuterol administration. Albuterol sulfate hydrofluoroalkane (360 µg, 4 puffs) was administered through a metered-dose inhaler by using a spacer device (AeroChamber Plus Flow-Vu; Monaghan Medical, Plattsburgh, NY), and lung function was measured 15 minutes later. Patients with 12% or less improvement in FEV<sub>1</sub> after the first albuterol dose received a second dose (360 µg for those ≥18 years and 180 µg for those <18 years), and lung function was remeasured after another 15-minute wait.

To receive 6 weeks of observed ICS treatment, study participants had to meet the following additional criteria: measured FEV<sub>1</sub> of between 40% and 90% of predicted value (based on age, sex, height, and race-ethnicity),<sup>11</sup> greater than 12% maximum bronchodilator reversibility, no smoking in the preceding year and less than 10 pack years of total smoking, no ICSs or systemic corticosteroids used in the preceding 4-week period, and not pregnant and not planning to become pregnant during the 6 weeks of ICS treatment. Patients in the SAPPHIRE cohort who both met these criteria and agreed to treatment received a 6-week course of beclomethasone dipropionate hydrofluoroalkane (320 µg/d administered as 2 puffs twice a day). Patients self-administered the ICS medication through a metered-dose inhaler and use of the previously described spacer device. At the end of the 6-week treatment period, patients returned to complete another staff-administered questionnaire and undergo lung function testing.

### Assessment of exposure and outcomes

Patient medication adherence was assessed by using a DOSER-CT device (Meditrack, Easton, Mass). The DOSER-CT was attached to the metered-dose inhaler, and it counted each time that the inhaler was actuated. Adherence was calculated as the total number of recorded actuations divided by the product of the number of days between visits and 4 (the prescribed number of ICS puffs per day).

To assess changes in the level of asthma control, we measured differences in Asthma Control Test (ACT; QualityMetric, Lincoln, RI) responses before and after the 6-week course of ICS therapy. We also assessed changes in prebronchodilator FEV<sub>1</sub> between these time points.

Genome-wide genotype data were collected for the African American SAPPHIRE participants in the treatment trial by using commercial arrays (Affymetrix, Santa Clara, Calif). We have previously used these data to calculate

the proportion of West African ancestry (heretofore called African ancestry) in these participants.<sup>12</sup> Briefly, the software program LAMP was used to estimate ancestry at each locus.<sup>13,14</sup> We then estimated each patient's global genetic ancestry (ie, proportion of African ancestry) as the proportion of African alleles among genotyped autosomal single nucleotide polymorphism locations.

### Statistical analysis

The primary outcome of the study was ICS response, as measured by the change in ACT score between the initial visit and the 6-week follow-up visit after ICS treatment (ie, the composite ACT<sub>[6 weeks]</sub> – ACT<sub>[initial]</sub>). The secondary outcome was the percentage change in prebronchodilator FEV<sub>1</sub> between these time points (ie, FEV<sub>1[6 weeks]</sub> – FEV<sub>1[initial]</sub>/FEV<sub>1[initial]</sub>). Linear regression was used to assess the relationship between both outcome variables and the following dependent variables: patient age, sex (coded male = 0, coded female = 1), self-reported race-ethnicity (coded European American = 0, coded African American = 1), body mass index (BMI), baseline percent predicted FEV<sub>1</sub>, baseline ACT score, and ICS adherence. Both age and BMI were modeled for each unit increase (ie, years and kilograms per meters squared, respectively) but were aggregated into 10-unit increments for presentation in the tables. Based on the original validation of the ACT by Nathan et al,<sup>15</sup> we also dichotomized the composite ACT score at a cut point of 19 (ie, patients with scores ≤19 were considered to have “not controlled” or “uncontrolled” asthma and patients with scores ≥20 were considered to have “controlled” asthma). Similarly, we dichotomized lung function at 70% of predicted FEV<sub>1</sub> based on the midpoint for persistent moderate asthma in the current US asthma guidelines.<sup>16</sup> Therefore we stratified our models by both baseline ACT score (ie, ≤19 and ≥20) and baseline percent predicted FEV<sub>1</sub> (ie, <70% and 70% to 90% [90% was the upper limit in the treatment group]) to assess the relationship between exposure variables and outcomes within strata that are considered to separate clinically meaningful differences in asthma control and severity. Separate adjusted models limited to African American participants were used to assess the relationship between African ancestry and ICS response.

As a *post hoc* analysis, we assessed factors associated with achieving self-reported asthma control (ACT score ≥20) after 6 weeks of ICS treatment among all patients whose asthma was not controlled at baseline (ACT score ≤19). Logistic regression was used to assess the likelihood of achieving control as a function of the following variables: patient age, sex (coded male = 0, coded female = 1), self-reported race-ethnicity (coded European American = 0, coded African American = 1), BMI, baseline percent predicted FEV<sub>1</sub>, and ICS adherence.

Analyses were performed with SAS statistical computing software (SAS Institute, Cary, NC).<sup>17</sup> A *P* value of less than .05 was considered statistically significant.

## RESULTS

Three hundred thirty-nine participants in the SAPPHIRE cohort met the criteria and completed 6 weeks of observed ICS treatment; 242 enrollees identified themselves as African American, and 97 identified as European American. The characteristics of those subjects before and after stratification by race-ethnicity are shown in Table I. When compared with European American participants, African American study subjects were significantly younger (mean, 32.5 vs 36.8 years), had a higher BMI (mean, 32.8 vs 29.4 kg/m<sup>2</sup>), and reported less well-controlled asthma (mean ACT score, 18.1 vs 20.0). African American subjects also had lower ICS adherence (mean, 0.76 vs 0.84), implying that on average, African American participants took 76% of their prescribed study dose compared with 84% in European American participants. The average estimated proportion of African ancestry in the African American participants was 79.9% ± 9.9% (SD), and the distribution is shown in Fig E1 in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org).

**TABLE I.** Characteristics of SAPHIRE study participants (n = 339)\*

Variable	Overall (n = 339)	African American (n = 242)	European American (n = 97)	P value†
Age (y), mean ± SD	33.7 ± 13.8	32.5 ± 13.1	36.8 ± 14.9	<.01
Female sex, no. (%)	198 (58.4)	148 (61.2)	50 (51.6)	.11
Self-reported race-ethnicity, no. (%)				—
African American	242 (71.4)	242 (100.0)	—	—
European American	97 (28.6)	—	97 (100.0)	—
Proportion of African Ancestry	—	79.9 ± 9.9	—	—
BMI (kg/m <sup>2</sup> ), mean ± SD†	31.9 ± 9.5	32.8 ± 9.6	29.4 ± 8.8	<.01
ACT score at enrollment, mean ± SD‡	18.6 ± 5.1	18.1 ± 5.2	20.0 ± 4.5	<.01
Percent predicted FEV <sub>1</sub> at enrollment, mean ± SD	72.9 ± 12.7	73.5 ± 12.4	71.2 ± 13.2	.13
Bronchodilator response at enrollment, mean ± SD§	20.5 ± 15.3	20.4 ± 13.1	20.6 ± 19.8	.91
Change in ACT score, mean ± SD	3.1 ± 4.8	3.3 ± 4.9	2.4 ± 4.6	.11
Percentage change in prebronchodilator FEV <sub>1</sub> , mean ± SD§	11.3 ± 18.1	10.6 ± 15.0	12.9 ± 24.2	.28
ICS adherence, mean ± SD; median; and interquartile range¶	0.79 ± 0.21; 0.84; 0.66-0.94	0.76 ± 0.22; 0.80; 0.61-0.93	0.84 ± 0.17; 0.89; 0.79-0.96	<.01

\*Race-ethnicity was determined based on participant self-report.

†P value for comparison of African American and European American subjects.

‡ACT scores of 19 or less represent poor asthma control, whereas those of 20 or greater represent good control.

§Bronchodilator response is measured as the percentage change in FEV<sub>1</sub> after administration of inhaled albuterol.

||Measured as the change between values measured at the time of enrollment and after 6 weeks of ICS treatment.

¶The mean, median, and interquartile range represent the proportion of the prescribed amount of ICS taken over 6 weeks of treatment.

Over the 6-week course of ICS treatment, the average improvement in ACT score and FEV<sub>1</sub> was similar among African American and European American participants. Improvements in ACT score were 3.3 and 2.4 points for African American and European American subjects, respectively ( $P = .11$ ). Similarly, pre-bronchodilator FEV<sub>1</sub> improved by 10.6% and 12.9%, respectively ( $P = .28$ ).

These above findings were supported in Table II, which examined the factors associated with change in ACT score and FEV<sub>1</sub> over the course of treatment. Self-identified race-ethnicity was not associated with change in ACT score or FEV<sub>1</sub>, even after accounting for other variables, including ICS adherence. After adjusting for all of the variables shown, baseline ACT score (parameter estimate [ $\beta$ ] =  $-0.71$ ,  $P < .01$ ), baseline percent predicted FEV<sub>1</sub> ( $\beta = 0.09$ ,  $P < .01$ ), degree of bronchodilator response ( $\beta = 0.05$ ,  $P < .01$ ), and ICS adherence ( $\beta = 2.38$ ,  $P < .01$ ) were significantly associated with the change in ACT score. In contrast, only degree of bronchodilator response was significantly associated with the change in FEV<sub>1</sub> with treatment in the multivariable model ( $\beta = 0.72$ ,  $P < .01$ ).

Because the effects of ICS adherence can differ with underlying asthma control or lung function, we stratified our analyses according to baseline ACT score (uncontrolled asthma = ACT score  $\leq 19$ ; controlled asthma = ACT score  $\geq 20$ ) and initial percent predicted FEV<sub>1</sub> (ie,  $<70\%$  and  $\geq 70\%$ ; Table III).<sup>16</sup> ICS adherence was found to be a significant predictor of ACT improvement among subjects with uncontrolled asthma at baseline ( $\beta = 3.95$ ,  $P = 0.04$ ). Although ICS adherence had a consistent and positive association with FEV<sub>1</sub> improvement in both lung function strata (percent predicted FEV<sub>1</sub>  $<70\%$  and  $\geq 70\%$ ), this association did not reach statistical significance in either group ( $\beta = 5.35$ ,  $P = .49$  and  $\beta = 4.19$ ,  $P = .22$ , respectively). Both percent predicted FEV<sub>1</sub> at baseline ( $\beta = 0.11$ ,  $P < .01$ ) and degree of bronchodilator response ( $\beta = 0.09$ ,  $P < .01$ ) were significantly

associated with a change in ACT score among those whose asthma was initially uncontrolled (ACT score  $\leq 19$ ). Bronchodilator response was associated with FEV<sub>1</sub> improvement among those in both lung function strata ( $P < .01$  for those with an initial percent predicted FEV<sub>1</sub>  $<70\%$  and  $\geq 70\%$ ). In none of these stratified models was self-reported race-ethnicity significantly associated with change in ACT score or change in FEV<sub>1</sub>.

We assessed whether African ancestry was a predictor of ICS responsiveness (Table IV).<sup>16</sup> Proportion of African ancestry was unrelated to ICS response, as measured by both the change in ACT score and the change in FEV<sub>1</sub>. African ancestry was similarly not related to ICS response, even after stratifying by baseline level of asthma control and lung function.

As a *post hoc* analysis, we assessed factors associated with the likelihood of achieving self-reported asthma control (ACT score  $\geq 20$ ) after 6 weeks of ICS treatment among all subjects whose asthma was not controlled at baseline (initial ACT score  $\leq 19$ ). As shown in Table E1 in this article's Online Repository at [www.jacionline.org](http://www.jacionline.org), age, initial percent predicted FEV<sub>1</sub>, and degree of bronchodilator response were associated with the likelihood of reporting controlled asthma at the 6-week treatment follow-up.

## DISCUSSION

Few studies have described the relationship between ICS treatment and the change in longitudinal measures of lung function and asthma control among African American subjects when compared with European American subjects. Here we demonstrate that neither self-identified race-ethnicity nor genetic ancestry were associated with ICS treatment response, as defined by a change in either ACT score or FEV<sub>1</sub>. This study builds on our earlier analysis in African American subjects alone, showing no relationship between African ancestry and change in FEV<sub>1</sub>.<sup>9</sup>

**TABLE II.** Predictors of ICS response measured as change in ACT score and change in lung function over 6 weeks of treatment\*

	Measure of ICS response							
	Change in ACT score*				Percentage change in FEV <sub>1</sub> †			
	Univariable parameter estimate (β)	P value	Multivariable parameter estimate (β)‡	P value	Univariable parameter estimate (β)	P value	Multivariable parameter estimate (β)‡	P value
Age (y)§	-0.10 ± 0.19	.62	-0.19 ± 0.14	.17	-0.07 ± 0.72	.92	-0.68 ± 0.57	.24
Sex	0.43 ± 0.53	.42	0.18 ± 0.36	.62	1.09 ± 1.99	.59	1.21 ± 1.52	.43
Race-ethnicity¶	0.93 ± 0.58	.11	-0.57 ± 0.40	.16	-2.36 ± 2.17	.28	-2.52 ± 1.69	.14
BMI§	0.35 ± 0.28	.20	-0.01 ± 0.19	.96	0.40 ± 1.04	.70	0.45 ± 0.81	.58
ACT score at baseline	-0.68 ± 0.04	<.01	-0.71 ± 0.04	<.01	-1.02 ± 0.19	<.01	-0.24 ± 0.16	.12
Percent predicted FEV <sub>1</sub> at baseline	-0.03 ± 0.02	.21	0.09 ± 0.02	<.01	-0.65 ± 0.07	<.01	-0.13 ± 0.07	.07
Bronchodilator response at baseline	0.09 ± 0.02	<.01	0.05 ± 0.01	<.01	0.80 ± 0.05	<.01	0.71 ± 0.06	<.01
ICS adherence	2.23 ± 1.26	.08	2.38 ± 0.84	<.01	3.78 ± 4.75	.43	5.68 ± 3.55	.11

\*ICS response was measured as the numeric change in composite ACT score from enrollment to follow-up after 6 weeks of ICS treatment.

†ICS response was measured as the percentage change in FEV<sub>1</sub> from enrollment to follow-up after 6 weeks of ICS treatment (ie, FEV<sub>1[6 weeks]</sub> - FEV<sub>1[initial]}/FEV<sub>1[initial]</sub>).</sub>

‡Adjusted for all other variables listed.

§These variables were modeled for a single-unit increase (ie, years and kilograms per meters squared for age and BMI, respectively), but are aggregated here to show the effect of a 10-unit increase.

||Referent is male (coded male = 0, coded female = 1).

¶Referent is European American (coded European American = 0, coded African American = 1).

**TABLE III.** Predictors of ICS response stratified by baseline ACT score and baseline FEV<sub>1</sub>\*

	Measure of ICS response							
	Change in ACT score*				Percentage change in FEV <sub>1</sub> †			
	Initial ACT score ≤19		Initial ACT score ≥20		Initial percent predicted FEV <sub>1</sub> <70%		Initial percent predicted FEV <sub>1</sub> ≥70%	
	Parameter estimate (β)‡	P value	Parameter estimate (β)‡	P value	Parameter estimate (β)‡	P value	Parameter estimate (β)‡	P value
Age (y)§	-0.35 ± 0.33	.29	0.06 ± 0.14	.70	-0.32 ± 1.35	.81	-0.61 ± 0.52	.24
Sex	0.28 ± 0.83	.73	0.33 ± 0.40	.40	1.64 ± 3.38	.63	1.01 ± 1.41	.48
Race-ethnicity¶	0.48 ± 1.00	.63	-0.17 ± 0.41	.69	-5.70 ± 3.76	.13	-0.84 ± 1.57	.59
BMI§	-0.07 ± 0.43	.88	0.13 ± 0.22	.55	-0.26 ± 1.58	.87	0.96 ± 0.84	.25
ACT score at baseline	—	—	—	—	-0.63 ± 0.32	.06	0.002 ± 0.16	.99
Percent predicted FEV <sub>1</sub> at baseline	0.11 ± 0.04	<.01	0.03 ± 0.02	.16	—	—	—	—
Bronchodilator response at baseline	0.09 ± 0.03	<.01	0.02 ± 0.03	.56	0.74 ± 0.08	<.01	0.63 ± 0.09	<.01
ICS adherence	3.95 ± 1.94	.04	1.41 ± 0.95	.14	5.35 ± 7.69	.49	4.19 ± 3.38	.22

\*ICS response was measured as the numeric change in composite ACT score from enrollment to follow-up after 6 weeks of ICS treatment. The analysis was stratified by what was clinically considered to be uncontrolled asthma (ACT score ≤19) and controlled asthma (ACT score ≥20) at baseline.

†ICS response was measured as the percentage change in FEV<sub>1</sub> from enrollment to follow-up after 6 weeks of ICS treatment (ie, FEV<sub>1[6 weeks]</sub> - FEV<sub>1[initial]}/FEV<sub>1[initial]</sub>). The analysis was stratified by percent predicted FEV<sub>1</sub> measured at baseline (ie, a cut point of 70% of predicted FEV<sub>1</sub>, which is the midpoint for persistent moderate severity asthma in the current US asthma guidelines).<sup>16</sup></sub>

‡Adjusted for all other variables listed.

§These variables were modeled for a single-unit increase (ie, years and kilograms per meters squared for age and BMI, respectively) but are aggregated here to show the effect of a 10-unit increase.

||Referent is male (coded male = 0, coded female = 1).

¶Referent is European American (coded European American = 0, coded African American = 1).

The average improvement in FEV<sub>1</sub> was 11.3% in our overall study population. This is similar to our previous study, in which we observed an 11.6% improvement in FEV<sub>1</sub> after 6 weeks of ICS therapy.<sup>9</sup> This magnitude of FEV<sub>1</sub> improvement is similar to that described by some<sup>18</sup> but higher than seen by others.<sup>19,20</sup> Part of these differences might be due to the relatively high level of medication adherence in the current study. We observed an average adherence of 79%, which is higher than that usually seen in unselected populations of ICS-treated asthmatic patients.<sup>3,4</sup> This high level of adherence might be due to participants knowing that adherence was being monitored, as has been

observed in other studies in which patients were conscious of adherence monitoring.<sup>21-23</sup>

Although we found that neither self-identified race-ethnicity nor ancestry was associated with ICS response, our earlier work showed African ancestry to be associated with asthma exacerbations,<sup>24</sup> nocturnal asthma,<sup>12</sup> and lung function.<sup>25</sup> Perhaps this indicates that although the genetic determinates of ICS controller response do not differ among African American and European American subjects, determinates of intrinsic disease severity do differ. The implication here would be that genetic ancestry has little independent contribution to drug response

**TABLE IV.** Assessment of genetic ancestry as a predictor of ICS response among African American subjects with asthma

	Measure of ICS response											
	Change in ACT score*						Percentage change in FEV <sub>1</sub> †					
	All subjects		Initial ACT score ≤19		Initial ACT score ≥20		All subjects		Initial percent predicted FEV <sub>1</sub> <70%		Initial percent predicted FEV <sub>1</sub> ≥70%	
	Parameter estimate (β)‡	P value	Parameter estimate (β)‡	P value	Parameter estimate (β)‡	P value	Parameter estimate (β)‡	P value	Parameter estimate (β)‡	P value	Parameter estimate (β)‡	P value
Age (y)§	-0.44 ± 0.19	.02	-0.85 ± 0.38	.03	0.04 ± 0.23	.86	-0.27 ± 0.72	.71	2.08 ± 1.77	.25	-0.67 ± 0.71	.35
Sex	0.54 ± 0.49	.27	0.57 ± 0.95	.55	0.88 ± 0.59	.14	1.73 ± 1.86	.35	3.07 ± 4.22	.47	1.04 ± 1.89	.58
Proportion of African Ancestry¶	1.63 ± 2.30	.48	1.37 ± 4.69	.77	0.67 ± 2.71	.81	2.96 ± 8.75	.74	4.80 ± 22.52	.83	2.45 ± 8.51	.77
BMI§	0.05 ± 0.26	.84	0.13 ± 0.49	.79	-0.01 ± 0.31	.98	-0.37 ± 0.97	.70	-1.38 ± 1.99	.49	-0.08 ± 1.06	.94
ACT score at baseline	-0.69 ± 0.05	<.01	—	—	—	—	-0.17 ± 0.18	.35	-0.71 ± 0.41	.09	0.15 ± 0.20	.44
Percent predicted FEV <sub>1</sub> at baseline	0.09 ± 0.03	<.01	0.06 ± 0.04	.19	0.06 ± 0.04	.14	-0.10 ± 0.10	.29	—	—	—	—
Bronchodilator response at baseline	0.07 ± 0.02	<.01	0.07 ± 0.04	.07	0.07 ± 0.04	.05	0.52 ± 0.09	<.01	0.52 ± 0.13	<.01	0.56 ± 0.12	<.01
ICS adherence	3.92 ± 1.12	<.01	7.84 ± 2.22	<.01	2.45 ± 1.37	.08	7.18 ± 4.28	.10	11.53 ± 9.08	.21	4.56 ± 4.64	.33

\*ICS response was measured as the numeric change in the composite ACT score from enrollment to follow-up after 6 weeks of ICS treatment. The ACT is stratified by what is clinically considered to be uncontrolled asthma (ACT score ≤19) and controlled asthma (ACT score ≥20).

†ICS response was measured as the percentage change in FEV<sub>1</sub> from enrollment to follow-up after 6 weeks of ICS treatment (ie, FEV<sub>1</sub>[6 weeks] - FEV<sub>1</sub>[initial]/FEV<sub>1</sub>[initial]). The analysis was stratified by percent predicted FEV<sub>1</sub> measured at baseline (ie, a cut point of 70% of predicted FEV<sub>1</sub>, which is the midpoint for persistent moderate severity asthma in the current US asthma guidelines).<sup>16</sup>

‡Adjusted for all other variables listed.

§These variables were modeled for a single-unit increase (ie, years and kilograms per meters squared for age and BMI, respectively) but are aggregated here to show the effect of a 10-unit increase.

||Referent is male (coded male = 0, coded female = 1).

¶Modeled as effect of each percentage increase in the proportion of overall African ancestry, as measured by using genome-wide genotype data.

beyond that already captured through baseline measures of asthma severity, asthma control, and lung function. Another potentially important implication of our findings is that differences in corticosteroid response are unlikely to account for between-group differences in asthma control and complication rates observed for African American and European American subjects on a population level.<sup>26,27</sup>

It is important to note that the lack of association for overall African ancestry should not be interpreted as an absence of population-specific pharmacogenomics variants. Genetic variants that influence drug response can occur exclusively or at different frequencies between population groups.<sup>28,29</sup> However, in a recent review of the pharmacogenomics of the ICS response,<sup>30</sup> none of the existing genome-wide association studies included substantial numbers of African American subjects. Therefore it is not known whether the risk variants that have been identified to date are generalizable to multiple population groups. Our results do not address the generalizability of existing pharmacogenomic associations. Rather, our study implies that the sum effect of genetic variants influencing ICS response is likely to be similar among subjects of African and European descent.

Our study is not without other limitations. First, the subjects in our study were all members of a single large health system in southeast Michigan; therefore the findings from our study might not be generalizable to other patient populations within the United States. However, the proportion of West African ancestry estimated for the subjects in our study is similar to that reported for other African American groups throughout the United States.<sup>31,32</sup>

Second, because we did not have admixture estimates in our European American participants, we could not assess the effect of ancestry within this group. However, there is no *a priori* reason to suspect that the effect of genetic ancestry would have differed between groups, and the lower degree of continental ancestral variation in European American subjects would have required a much greater number of subjects to perform the same assessment.<sup>33,34</sup>

Third, although this study did include both African American and European American subjects, the latter comprised a much smaller number of patients. Consequently, additional replication is needed to bolster our findings.

In this burgeoning era of personalized genomics, there is an increased effort to target therapies to subjects most likely to respond to treatment. Differences in medication response and treatment-related side effects by race-ethnicity have now been noted for a number of medications.<sup>35-37</sup> Fortunately, African American subjects, who as a group disproportionately have asthma complications,<sup>38,39</sup> did not demonstrate response differences to ICS medication, the cornerstone treatment for persistent asthma. African American and European American subjects appeared to equally enjoy the benefits of ICS treatment for improving asthma control and lung function. In identifying subjects most likely to benefit from treatment, our study suggested that arguably more mundane factors, such as medication adherence, level of bronchodilator responsiveness, baseline lung function, and patient-reported asthma control, were consistently predictive of ICS response. Therefore although pharmacogenomics might eventually pave the way for more targeted asthma


treatment, fundamental characteristics of disease severity/control and management remain primary concerns for selecting and optimizing treatment.<sup>16</sup>

#### Key messages

- Neither self-reported race-ethnicity nor African ancestry appears to be a major driver of ICS treatment response, strongly suggesting that this cornerstone therapy is equally beneficial in treating African American and European American subjects.
- Easily obtained measures of lung function and asthma control might be useful in assessing the likelihood of response.

#### REFERENCES

1. Bender B, Milgrom H, Apter A. Adherence intervention research: what have we learned and what do we do next? *J Allergy Clin Immunol* 2003;112:489-94.
2. Apter AJ, Reisine ST, Affleck G, Barrows E, ZuWallack RL. The influence of demographic and socioeconomic factors on health-related quality of life in asthma. *J Allergy Clin Immunol* 1999;103:72-8.
3. Williams LK, Joseph CL, Peterson EL, Wells K, Wang M, Chowdhry VK, et al. Patients with asthma who do not fill their inhaled corticosteroids: a study of primary nonadherence. *J Allergy Clin Immunol* 2007;120:1153-9.
4. Williams LK, Pladevall M, Xi H, Peterson EL, Joseph C, Lafata JE, et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. *J Allergy Clin Immunol* 2004;114:1288-93.
5. Williams LK, Peterson EL, Wells K, Ahmedani BK, Kumar R, Burchard EG, et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. *J Allergy Clin Immunol* 2011;128:1185-91.
6. Wells KE, Peterson EL, Ahmedani BK, Severson RK, Gleason-Comstock J, Williams LK. The relationship between combination inhaled corticosteroid and long-acting beta-agonist use and severe asthma exacerbations in a diverse population. *J Allergy Clin Immunol* 2012;129:1274-9.
7. Williams LK, Joseph CL, Peterson EL, Moon C, Xi H, Krajenta R, et al. Race-ethnicity, crime, and other factors associated with adherence to inhaled corticosteroids. *J Allergy Clin Immunol* 2007;119:168-75.
8. Apter AJ, Boston RC, George M, Norfleet AL, Tenhave T, Coyne JC, et al. Modifiable barriers to adherence to inhaled steroids among adults with asthma: it's not just black and white. *J Allergy Clin Immunol* 2003;111:1219-26.
9. Gould W, Peterson EL, Karungi G, Zoratti A, Gaggin J, Toma G, et al. Factors predicting inhaled corticosteroid responsiveness in African American patients with asthma. *J Allergy Clin Immunol* 2010;126:1131-8.
10. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. *Eur Respir J* 2005;26:319-38.
11. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. *Am J Respir Crit Care Med* 1999;159:179-87.
12. Levin AM, Wang Y, Wells KE, Padhukasahasram B, Yang JJ, Burchard EG, et al. Nocturnal asthma and the importance of race/ethnicity and genetic ancestry. *Am J Respir Crit Care Med* 2014;190:266-73.
13. Sankararaman S, Sridhar S, Kimmel G, Halperin E. Estimating local ancestry in admixed populations. *Am J Hum Genet* 2008;82:290-303.
14. Pasaniuc B, Sankararaman S, Kimmel G, Halperin E. Inference of locus-specific ancestry in closely related populations. *Bioinformatics* 2009;25:1213-21.
15. Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, et al. Development of the asthma control test: a survey for assessing asthma control. *J Allergy Clin Immunol* 2004;113:59-65.
16. Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma—summary report 2007. *J Allergy Clin Immunol* 2007;120(suppl):S94-138.
17. SAS/STAT user's guide. Version 9.2. Cary (NC): SAS Institute; 2008.
18. Szefer SJ, Martin RJ, King TS, Boushey HA, Cherniack RM, Chinchilli VM, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. *J Allergy Clin Immunol* 2002;109:410-8.
19. Martin RJ, Szefer SJ, King TS, Kraft M, Boushey HA, Chinchilli VM, et al. The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial. *J Allergy Clin Immunol* 2007;119:73-80.
20. Tantisira KG, Lake S, Silverman ES, Palmer LJ, Lazarus R, Silverman EK, et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. *Hum Mol Genet* 2004;13:1353-9.
21. Onyirimba F, Apter A, Reisine S, Litt M, McCusker C, Connors M, et al. Direct clinician-to-patient feedback discussion of inhaled steroid use: its effect on adherence. *Ann Allergy Asthma Immunol* 2003;90:411-5.
22. Pladevall M, Brotons C, Gabriel R, Arnau A, Suarez C, de la Figuera M, et al. Multicenter cluster-randomized trial of a multifactorial intervention to improve antihypertensive medication adherence and blood pressure control among patients at high cardiovascular risk (the COM99 study). *Circulation* 2010;122:1183-91.
23. Reddel HK, Toelle BG, Marks GB, Ware SI, Jenkins CR, Woolcock AJ. Analysis of adherence to peak flow monitoring when recording of data is electronic. *BMJ* 2002;324:146-7.
24. Rumpel JA, Ahmedani BK, Peterson EL, Wells KE, Yang M, Levin AM, et al. Genetic ancestry and its association with asthma exacerbations among African American subjects with asthma. *J Allergy Clin Immunol* 2012;130:1302-6.
25. Kumar R, Seibold MA, Aldrich MC, Williams LK, Reiner AP, Colangelo L, et al. Genetic ancestry in lung-function predictions. *N Engl J Med* 2010;363:321-30.
26. Mannino DM, Homa DM, Akinbami LJ, Moorman JE, Gwynn C, Redd SC. Surveillance for asthma—United States, 1980-1999. *MMWR Surveill Summ* 2002;51:1-13.
27. Asthma prevalence and control characteristics by race/ethnicity—United States, 2002. *MMWR Morb Mortal Wkly Rep* 2004;53:145-8.
28. Drozda K, Wong S, Patel SR, Bress AP, Nutescu EA, Kittles RA, et al. Poor warfarin dose prediction with pharmacogenetic algorithms that exclude genotypes important for African Americans. *Pharmacogenet Genomics* 2015;25:73-81.
29. Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, et al. Identification and functional characterization of a new CYP2C9 variant (CYP2C9\*5) expressed among African Americans. *Mol Pharmacol* 2001;60:382-7.
30. Davis JS, Weiss ST, Tantisira KG. Asthma pharmacogenomics: 2015 update. *Curr Allergy Asthma Rep* 2015;15:42.
31. Tishkoff SA, Reed FA, Friedlaender FR, Ehret C, Ranciaro A, Froment A, et al. The genetic structure and history of Africans and African Americans. *Science* 2009;324:1035-44.
32. Bryc K, Auton A, Nelson MR, Oksenberg JR, Hauser SL, Williams S, et al. Genome-wide patterns of population structure and admixture in West Africans and African Americans. *Proc Natl Acad Sci U S A* 2010;107:786-91.
33. Yang JJ, Burchard EG, Choudhry S, Johnson CC, Ownby DR, Favro D, et al. Differences in allergic sensitization by self-reported race and genetic ancestry. *J Allergy Clin Immunol* 2008;122:820-7.
34. Sinha M, Larkin EK, Elston RC, Redline S. Self-reported race and genetic admixture. *N Engl J Med* 2006;354:421-2.
35. Chen P, Lin JJ, Lu CS, Ong CT, Hsieh PF, Yang CC, et al. Carbamazepine-induced toxic effects and HLA-B\*1502 screening in Taiwan. *N Engl J Med* 2011;364:1126-33.
36. Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. *Pharmacogenet Genomics* 2006;16:101-10.
37. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. *Vasodilator-Heart Failure Trial Study Group. J Card Fail* 1999;5:178-87.
38. Akinbami LJ, Moorman JE, Simon AE, Schoendorf KC. Trends in racial disparities for asthma outcomes among children 0 to 17 years, 2001-2010. *J Allergy Clin Immunol* 2014;134:547-53.e5.
39. Akinbami LJ, Moorman JE, Bailey C, Zahran HS, King M, Johnson CA, et al. Trends in asthma prevalence, health care use, and mortality in the United States, 2001-2010. *NCHS Data Brief* 2012;94:1-8.



**FIG E1.** Distribution of genetic ancestry among African American study participants with genome-wide genotype data is shown ( $n = 195$ ). Each column represents an individual study participant. The percentage of African ancestry is depicted in *blue*, and the percentage of European ancestry is depicted in *yellow*.

**TABLE E1.** Likelihood of achieving asthma control among subjects whose self-reported asthma was not controlled at baseline\*

	aOR (95% CI)†	P value
Age (y)‡	0.71 (0.53-0.96)	.02
Sex§	1.62 (0.77-3.41)	.20
Race-ethnicity	0.60 (0.23-1.51)	.28
BMI‡	0.70 (0.48-1.03)	.07
Percent predicted FEV <sub>1</sub> at baseline	1.05 (1.01-1.08)	<.01
Bronchodilator response at baseline	1.03 (1.00-1.06)	.03
ICS adherence	1.01 (0.19-5.35)	.99

aOR, Adjusted odds ratio.

\*Odds ratios represent the likelihood of achieving self-reported asthma control (composite ACT score  $\geq 20$ ) among patients whose baseline ACT score was 19 or less (ie, uncontrolled asthma).

†The odds ratio for each dependent variable is adjusted for all of the other variables shown.

‡These variables were modeled for a single-unit increase (ie, years and kilograms per meters squared for age and BMI, respectively) but are aggregated here to show the effect of a 10-unit increase.

§Referent is male (coded male = 0, coded female = 1).

||Referent is European American (coded European American = 0, coded African American = 1).